Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
Just how independent is Genentech?
Questions continue to swirl as the unit mulls another oncology makeover.
CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Agenus looks to new deals and an ex-US path
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
